TrialClinical pharmacology and therapeutics2025

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.

Jue Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.